Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.

Saved in:
Bibliographic Details
Title: Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
Authors: Roblin X; Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France., Nancey S; Department of Gastroenterology, Lyon Sud hospital, Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France., Papamichael K; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Duru G; Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France., Flamand M; Clinique gastroentérologique Nantes, Nantes, France., Kwiatek S; Service gastroentérologie CHU Saint Pierre Ile de la reunion, Saint Pierre, Reunion., Cheifetz A; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Fabien N; Department of immunology University Claude Bernard, Lyon, France., Barrau M; Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France., Paul S; Immunology laboratory, CIC1408, University Hospital of Saint-Etienne, Saint-Etienne, France., CIRI [Centre International de Recherche en Infectiologie], Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, France.
Source: Journal of Crohn's & colitis [J Crohns Colitis] 2024 May 31; Vol. 18 (5), pp. 679-685.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium: Internet ISSN: 1876-4479 (Electronic) Linking ISSN: 18739946 NLM ISO Abbreviation: J Crohns Colitis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Be the first to leave a comment!
You must be logged in first